The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line
Official Title: Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.
Study ID: NCT01127841
Brief Summary: Evaluate the effectiveness of rituximab, bendamustine (r) in terms of complete response and response complete not confirmed.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hospital de Elche, Elche, Alicante, Spain
Hospital San Pedro de La Rioja, Logroño, La Rioja, Spain
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
Hospital Costa del Sol, Marbella, Malaga, Spain
Hospital Sant Joan de Reus, Reus, Tarragona, Spain
Hospital G. U. de Alicante, Alicante, , Spain
Hospital Insular de Gran Canarias, Canarias, , Spain
Hospital U. de Gran Canarias Dr. Negrín, Canarias, , Spain
Hospital uan Ramón Jiménez, Huelva, , Spain
Hospital Son Dureta, Mallorca, , Spain
Hospital Universitario Virgen de la Victoria, Málaga, , Spain
Complejo Hospitalario de Pontevedra, Pontevedra, , Spain
Instituto Oncologico de San Sebastian, San Sebastian, , Spain
Hospital Virgen de la Macarena, Sevilla, , Spain
Hospital Universitario de Canarias, Tenerife, , Spain
Hospital Virgen de la Salud, Toledo, , Spain
Hospital General de Valencia, Valencia, , Spain
Hospital Universitario La Fe, Valencia, , Spain